Wide Ranks

KNSA

Kiniksa Pharmaceuticals, Ltd.

22.32

Top Statistics
Market Cap 1 B Forward PE 32.66 Revenue Growth 67.40 %
Current Ratio 3.24 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -2.36 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -57.31 Enterprise / Revenue 3.64 Price To Sales Trailing12 Months 4.20
Profitability
Profit Margins -2.36 % Operating Margins -8.61 %
Balance Sheet
Total Cash 223 M Total Cash Per Share 3.10 Total Debt 10 M
Total Debt To Equity 2.42 Current Ratio 3.24 Book Value Per Share 6.06
All Measures
Short Ratio 1239.00 % Message Board Id finmb_558211765 Shares Short Prior Month 4 M
Return On Equity -0.0215 City London Uuid 7ea20e71-749b-31b8-994b-79f75933ead7
Previous Close 22.04 First Trade Date Epoch Utc 1 B Book Value 6.06
Beta 0.3480 Total Debt 10 M Volume 158928
Price To Book 3.69 Fifty Two Week Low 15.82 Total Cash Per Share 3.10
Total Revenue 384 M Shares Short Previous Month Date 1 B Target Median Price 35.00
Max Age 86400 Recommendation Mean 1.33 Sand P52 Week Change 0.3133
Operating Margins -8.61 % Target Mean Price 36.00 Net Income To Common -9068000
Short Percent Of Float 0.1274 Implied Shares Outstanding 72 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 255240 Average Volume10days 255240
Total Cash 223 M Next Fiscal Year End 1 B Revenue Per Share 5.42
Held Percent Insiders 0.0412 Ebitda Margins -6.35 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 22.04
Target Low Price 32.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 24.10
Open 22.10 Free Cashflow 25 M Dividend Yield 0.00 %
Return On Assets -0.0316 Time Zone Short Name EST Trailing Eps -0.1200
Day Low 21.93 Address1 23 Old Bond Street Shares Outstanding 41 M
Price Hint 2 Target High Price 40.00 Website https://www.kiniksa.com
52 Week Change 0.3803 Average Volume 363764 Forward Eps 0.5500
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 259.20 %
Is_sp_500 False Regular Market Day High 22.48 Profit Margins -2.36 %
Debt To Equity 2.42 Fifty Two Week High 28.15 Day High 22.48
Shares Short 4 M Regular Market Open 22.10 Industry Key drug-manufacturers-specialty-generic
Earnings Growth 0.00 % Enterprise To Revenue 3.64 Revenue Growth 67.40 %
Shares Percent Shares Out 0.0570 Operating Cashflow 11 M Currency USD
Time Zone Full Name America/New_York Market Cap 1 B Is_nasdaq_100 False
Zip WIS 4PZ Quote Type EQUITY Industry Drug Manufacturers - Specialty & Generic
Long Name Kiniksa Pharmaceuticals International, plc Regular Market Day Low 21.93 Held Percent Institutions 0.9797
Current Price 22.32 Address2 Floor 3 Enterprise To Ebitda -57.31
Financial Currency USD Current Ratio 3.24 Gross Margins 61.04 %
Industry Disp Drug Manufacturers - Specialty & Generic Number Of Analyst Opinions 6 Country United Kingdom
Float Shares 15 M Two Hundred Day Average 21.86 Enterprise Value 1 B
Price To Sales Trailing12 Months 4.20 Forward PE 32.66 Regular Market Volume 158928
Ebitda -24401000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.

Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.

The company was incorporated in 2015 and is based in London, the United Kingdom.